-
Mashup Score: 4
SUO 2022, one in 5 men with localized prostate cancer will develop mental illness, mental illness and suicidality in men with prostate cancer, CEASAR cohort, Veterans Affairs cohort, Zachary Klaassen.
Source: www.urotoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @zklaassen_md: Better synopsis written by @WallisCJD for @urotoday https://t.co/qW3eJDabqb #SUO22 https://t.co/DQYit7rvKT
-
-
Mashup Score: 3
Barriers exist in identifying risk, but strategies are available
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Whether it's due to the side effects of local and systemic therapies, or the diagnosis itself, men with #prostatecancer are at increased risk of mental distress and suicide, reported @zklaassen_md, of @GACancerCenter @mcg_urology, at #SUO22. https://t.co/e4I9YfTBc3 @UroOnc
-
-
Mashup Score: 0Aging U.S. Population a Challenge for Oncologists - 1 year(s) ago
Older patients will have different care goals, preferences, geriatric oncologist says
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
"My patients have taught me a lot about what is important to them, and they do worry about their cancer," said @Tullika_Garg, a specialist in geriatric oncology at @PennStHershey. https://t.co/9mQA9QMY4L #SUO22 @UroOnc #OncTwitter
-
-
Mashup Score: 0TULSA compared with radical prostatectomy in phase 3 trial - 1 year(s) ago
The phase 3 CAPTAIN trial was launched following the pivotal TACT trial, which showed that TULSA provided durable disease control with low toxicity at 3 years’ follow-up in men with localized prostate cancer.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
TULSA compared with radical prostatectomy in phase 3 trial https://t.co/8j8prMGolg #urology #urologist #SUO22 #prostatecancer
-
-
Mashup Score: 0
“Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Rollover data from OLYMPUS trial show long-term durability of LG-UTUC treatment https://t.co/k00xdVaCf3 #SUO22 #urology #urologist #UTUC #urothelialcancer
-
-
Mashup Score: 0Latest research supporting stereotactic radiotherapy for oligometastatic renal cell carcinoma - 1 year(s) ago
“Stereotactic radiation can delay the initiation of systemic therapy; it can locally control oligometastatic RCC patients for as much as 2 years,” says Raquibul Hannan, MD, PhD.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Latest research supporting stereotactic radiotherapy for oligometastatic renal cell carcinoma https://t.co/vtY51fq3FN #SUO22 #urology #urologist #kidneycancer
-
-
Mashup Score: 0
A single-institution study revealed that 37% of patients who underwent radical cystectomy experienced at least 1 additional intervention.
Source: Renal and Urology NewsCategories: Latest Headlines, UrologyTweet-
Complications Requiring Reoperation Common After Radical Cystectomy https://t.co/jNK8vnDdrM #SUO22 #blcsm
-
-
Mashup Score: 0Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting - 1 year(s) ago
SUO 2022 Blue Light Cystoscopy (BLC®) decreases the risk and prolongs time to recurrence based on Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with Cysview® Registry database.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
New evidence of the positive impact of #BlueLight cystoscopy on recurrence in #BladderCancer presented at the annual @UroOnc meeting #SUO22. #ReadNow details on UroToday > https://t.co/iCO0PrEyYr @Cysview @PhotocureASA @siadaneshmand https://t.co/EdRgHJslpz
-
-
Mashup Score: 0SUO 2022: BCG Naïve - FDA: 1 Year from Symposia - 1 year(s) ago
SUO 2022 trials in the non-muscle invasive bladder cancer BCG naïve space, SWOG S1605 trial, BCG shortage, BCG-naïve patients, Tice BCG, BCG full dose induction therapy.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
BCG naïve - FDA: 1 year from symposia. Presentation by Seth Lerner, MD, FACS @bcmhouston. #SUO22 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/JM8x7JAggf @UroOnc @SUO_YUO https://t.co/gEfClCR2ol
-
-
Mashup Score: 0
SUO 2022 intermediate risk non-muscle invasive bladder cancer, bladder cancer diagnosis, Ta high-grade tumors, BCG unresponsiveness, International Bladder Cancer Group, Ashish Kamat.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Intermediate risk non-muscle invasive #BladderCancer: “New” definitions. Presentation by @UroDocAsh @MDAndersonNews. #SUO22 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/FlzNCdyGYQ @UroOnc @SUO_YUO https://t.co/4woC3s4hta
-
Better synopsis written by @WallisCJD for @urotoday https://t.co/qW3eJDabqb #SUO22 https://t.co/px0FZ1eutR https://t.co/DQYit7rvKT